Open-label Study of Safety and Tolerability of Memantine in Children With Autism

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of autism in pediatric patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Collaborator: Merz Pharmaceuticals GmbH
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Completed lead-in study MEM-MD-57A (NCT00872898)

• A knowledgeable caregiver capable of providing reliable information about the patient's condition, able to attend all clinic visits with the patient

Exclusion Criteria:

• Patients with a concurrent medical condition that might interfere with the conduct of the study